NCT05937438View on ClinicalTrials.gov

Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2026

Conditions

Esophageal Carcinoma

Interventions

DRUG

Immune Checkpoint Inhibitors

Patients assigned to experimental arm would receive the maintenance treatment of immune checkpoint inhibitor (Tislelizumab or Camrelizumab) after postoperative radiotherapy for one year

Trial Locations (1)

Unknown

RECRUITING

Anhui Provicial Hospital, Hefei

All Listed Sponsors

lead

Anhui Provincial Hospital

OTHER_GOV